Brief: Valneva FY Total Revenues EUR 174.7 Mln
19/02/2026 06:14
Feb 19 (Reuters) - Valneva SE VLS.PA: VALNEVA REPORTS PRELIMINARY UNAUDITED 2025 REVENUE AND CASH AND PROVIDES 2026 OUTLOOK FY TOTAL REVENUES OF EUR 174.7 MILLION FIRST PHASE 3 DATA READOUT FOR LYME DISEASE VACCINE CANDIDATE ANTICIPATED IN FIRST HALF OF 2026 TOTAL REVENUES FOR 2026 ARE EXPECTED IN RANGE OF EUR 155-170 MILLION Source text: ID:nGNX1WCrqv Further company coverage: VLS.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48587696600;;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency